Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 45,477 |
|
|||||
| News | - | ||||||
| Day High | 52.33 | Low High |
|||||
| Day Low | 50.04 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Korro Bio Inc | KRRO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 1.05 | 2.09% | 51.30 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 50.04 | 50.04 | 52.33 | 51.30 | 50.25 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,440 | 45,477 | $ 51.32 | $ 2,333,867 | - | 13.00 - 97.91 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:02:07 | 7 | $ 51.30 | USD |
Korro Bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 37.96M | 738.53k | - | 0 | -81.17M | -109.91 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Korro Bio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KRRO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 48.49 | 52.35 | 46.66 | 49.71 | 43,961 | 2.81 | 5.80% |
| 1 Month | 58.22 | 60.18 | 46.41 | 51.67 | 38,231 | -6.92 | -11.89% |
| 3 Months | 49.00 | 97.91 | 46.41 | 63.77 | 42,394 | 2.30 | 4.69% |
| 6 Months | 40.87 | 97.91 | 38.7465 | 58.63 | 36,158 | 10.43 | 25.52% |
| 1 Year | 13.00 | 97.91 | 13.00 | 53.52 | 43,351 | 38.30 | 294.62% |
| 3 Years | 13.00 | 97.91 | 13.00 | 53.52 | 43,351 | 38.30 | 294.62% |
| 5 Years | 13.00 | 97.91 | 13.00 | 53.52 | 43,351 | 38.30 | 294.62% |
Korro Bio Description
| Frequency Therapeutics Inc is a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by degenerative diseases. Its Progenitor Cell Activation approach uses combinations of molecules to activate progenitor cells within the body to create functional tissue. Its product candidate FX-322 is being developed for treating sensorineural hearing loss. |
